Literature DB >> 23244807

Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy--Leukemia (FACT-Leu) questionnaire.

David Cella1, Sally E Jensen, Kimberly Webster, Du Hongyan, Jin-Shei Lai, Steven Rosen, Martin S Tallman, Susan Yount.   

Abstract

OBJECTIVE: Develop and validate a health-related quality-of-life (measure for patients with acute and chronic leukemia.
METHODS: The study consisted of two phases: scale construction and scale validation. For the item-generation phase, a summary of the literature combined with qualitative results from item-generation interviews with 29 acute or chronic leukemia patients and 16 health care providers yielded an initial item pool reflecting leukemia-specific concerns and symptoms. Items underwent iterations of review and reduction according to defined retention criteria to support content validity, as defined by priority concerns of patients. Seventeen final leukemia-specific items were combined with the Functional Assessment of Cancer Therapy-General to create the FACT-Leukemia (FACT-Leu) scale. For the validation phase, 79 individuals with acute or chronic leukemia completed questionnaires at three time points.
RESULTS: All FACT-Leu subscale and aggregated scores showed high internal consistency (αs ranging from 0.75 to 0.96). Test-retest reliability was adequate for all subscales (intraclass correlation range 0.765-0.890). The FACT-Leu scale demonstrated good convergent validity, with significant correlations with quality-of-life criteria and performance status, in the expected direction. FACT-Leu subscale scores were significantly different among the three performance status change groups, suggesting good responsiveness to change.
CONCLUSIONS: The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23244807     DOI: 10.1016/j.jval.2012.08.2210

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  44 in total

1.  International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

Authors:  Fabio Efficace; Michele Baccarani; Massimo Breccia; Susanne Saussele; Gregory Abel; Giovanni Caocci; Francois Guilhot; Kim Cocks; Adel Naeem; Mirjam Sprangers; Simone Oerlemans; Weichu Chie; Fausto Castagnetti; Felice Bombaci; Giora Sharf; Annarita Cardoni; Lucien Noens; Stephan Pallua; Marzia Salvucci; Ourania Nicolatou-Galitis; Gianantonio Rosti; Franco Mandelli
Journal:  Qual Life Res       Date:  2013-09-13       Impact factor: 4.147

2.  Symptom Management and Psychosocial Needs of Adults With Acute Myeloid Leukemia During Induction Treatment: A Pilot Study.

Authors:  Tara A Albrecht; Michael Boyiadzis; R K Elswick; Angela Starkweather; Margaret Rosenzweig
Journal:  Cancer Nurs       Date:  2017 Nov/Dec       Impact factor: 2.592

Review 3.  Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations.

Authors:  Jennifer E Vaughn; Sarah A Buckley; Roland B Walter
Journal:  Leuk Res       Date:  2016-04-01       Impact factor: 3.156

Review 4.  Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Authors:  Armin Rashidi; Roland B Walter; Martin S Tallman; Frederick R Appelbaum; John F DiPersio
Journal:  Blood       Date:  2016-06-27       Impact factor: 22.113

5.  Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.

Authors:  S Kurosawa; T Yamaguchi; T Mori; H Kanamori; Y Onishi; N Emi; S Fujisawa; A Kohno; C Nakaseko; B Saito; T Kondo; M Hino; Y Nawa; S Kato; A Hashimoto; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-06-15       Impact factor: 5.483

6.  A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Authors:  Eric Padron; Amy Dezern; Marcio Andrade-Campos; Kris Vaddi; Peggy Scherle; Qing Zhang; Yan Ma; Maria E Balasis; Sara Tinsley; Hanadi Ramadan; Cassandra Zimmerman; David P Steensma; Gail J Roboz; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

7.  Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Authors:  Jorge E Cortes; Carlo Gambacorti-Passerini; Michael W Deininger; Michael J Mauro; Charles Chuah; Dong-Wook Kim; Dragana Milojkovic; Philipp le Coutre; Valentin Garcia-Gutierrez; Rocco Crescenzo; Carla Mamolo; Arlene Reisman; Andreas Hochhaus; Tim H Brümmendorf
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-15       Impact factor: 4.553

Review 8.  A Systematic Review of Psychometric Properties of Health-Related Quality-of-Life and Symptom Instruments in Adult Acute Leukemia Survivors.

Authors:  Ashley Leak Bryant; AnnMarie Walton; Julia Shaw-Kokot; Deborah K Mayer; Bryce B Reeve
Journal:  Cancer Nurs       Date:  2016 Sep-Oct       Impact factor: 2.592

9.  The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data.

Authors:  Neha Kayastha; Steven P Wolf; Susan C Locke; Gregory P Samsa; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Support Care Cancer       Date:  2017-11-18       Impact factor: 3.603

10.  Quality of life from the perspective of the patient with acute myeloid leukemia.

Authors:  Sarah A Buckley; Diana Jimenez-Sahagun; Megan Othus; Roland B Walter; Stephanie J Lee
Journal:  Cancer       Date:  2017-09-07       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.